Common-Size Income Statement
Quarterly Data
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).
Income statement item | Description | The company |
---|---|---|
Operating income (loss) | The net result for the period of deducting operating expenses from operating revenues. | Cytokinetics Inc. operating income (loss) as a percentage of revenues decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Loss, before income tax provision | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | Cytokinetics Inc. loss, before income tax provision as a percentage of revenues decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Net loss | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Cytokinetics Inc. net loss as a percentage of revenues decreased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |